Going forward, the company will focus on its wholly owned subsidiary Medicinal Genomics Corporation, which conducts cannabis genetics research.
The SBIR Phase 1 award will go toward developing a test using immuno-PCR technology to detect toxins in medical marijuana.
The two firms are collaborating on a system to share genotypic, phenotypic, and treatment outcomes data with physicians on a mobile-device network.
Courtagen will use its ZiPhyr bioinformatics pipeline to help Astellas develop a predictive model that can be used in early-stage drug development.
The life sciences company can now offer its genetic tests in all 50 states in the US, as well as Canada and several other countries.
Proceeds from the financing will be used "to expand our ability to deliver leading-edge services to our customers," Courtagen's CEO said.
A spokesman for Courtagen, which develops NGS-based tests for ailments such as mitochondrial disorders, the $7.5 million is part of a financing round expected to bring in about $17 million.
The deals are with Pronto Diagnostics, headquartered in Tel Aviv, Israel and Medica Labs, based in Bangkok, Thailand.
NEW YORK (GenomeWeb) – Courtagen Life Sciences today announced a deal with Bioinn Molecular Diagnosis to provide Courtagen's clinical next-generation sequencing tests for neurological and metabolic disorders in Taiwan.
NEW YORK (GenomeWeb) – Courtagen Life Sciences has raised about $6.3 million, the genetic testing firm disclosed in a document filed with the US Securities and Exchange Commission this week.
A new study in JAMA finds that genetic tests might not be able to determine what diet is right for someone seeking to lose weight.
A genome-wide association study that linked common genetic variants to salivary gland carcinoma risk has been retracted, according to Retraction Watch.
Vampire bats' ability to live off blood is etched in their genomes and gut microbiomes, the Scientist reports.
In Genome Biology this week: peopling of the Sahara, epigenetic reprogramming analysis of liverwort, and more.